#Major Players in US Acute Myeloid Leukemia Market | Explore Tumblr Posts and Blogs

kenresearch1 · 10 months

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes

wellnessweb · 3 months

Text

Leukemia Therapeutics Market Size: Competitive Landscape Analysis

The Leukemia Therapeutics Market size was USD 16 Billion in 2023 and is expected to Reach USD 27.28 Billion by 2031 and grow at a CAGR of 6.9% over the forecast period of 2024-2031.The leukemia therapeutics market is experiencing rapid growth, driven by advancements in targeted therapies and personalized medicine. With an increasing understanding of the genetic and molecular mechanisms underlying various leukemia subtypes, pharmaceutical companies are developing innovative treatments that offer improved efficacy and reduced side effects. The market is also benefiting from a surge in research and development activities, coupled with supportive regulatory frameworks that expedite the approval process for novel drugs. Furthermore, the rise in leukemia prevalence, along with heightened awareness and early diagnosis, is expanding the patient pool eligible for these cutting-edge therapies. This dynamic landscape presents significant opportunities for stakeholders, ranging from biotech startups to established pharmaceutical giants, to make impactful contributions to leukemia care and patient outcomes.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/3135

Market Scope & Overview

The market report gives thorough information to help readers comprehend the current situation of the industry. The report relied on primary and secondary research, as well as private databases and a paid data source. The market research report sheds light on the history and future of the Leukemia Therapeutics Market business. The report analyses the market size and includes information on market drivers, limitations, and opportunities.

The market research report examines the primary strategies used by top industry players to advance their operations in the worldwide market while maintaining a competitive advantage over their competitors. The Leukemia Therapeutics Market study also depicts the competitive landscape of the industry's major competitors, as well as the top organizations’ percentage market share.

Market Segmentation Analysis

By Type

Chronic Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia

Acute Myeloid Leukemia

Others

By Drug Class

Targeted Therapy

Chemotherapy and Immunotherapy

By Distribution channel

Hospital Pharmacies

Online Providers

Drug Store

Retail Pharmacies

COVID-19 Pandemic Impact Analysis

In this Leukemia Therapeutics Market analysis, the impact of COVID-19 on the market is analyzed at both the global and country levels. According to this analysis, the COVID-19 pandemic and the post-pandemic phase had a significant impact on both the supply and demand sides of the market.

Regional Outlook

The report's accurate data will help market participants make informed decisions about regional expansions and investments. The report looks at the dynamics of the Leukemia Therapeutics Market in relation to worldwide market conditions.

Competitive Analysis

The data in this section will assist readers in understanding the primary strategies used by leading market players to control the global Leukemia Therapeutics Market . The research report includes a PORTER, SVOR, and PESTEL analysis, as well as an examination of the potential impact of microeconomic market variables. External and internal elements that are projected to have an impact on the company have been studied, presenting decision-makers with a clear picture of the industry's future.

Key Questions Answered in the Leukemia Therapeutics Market Report

What is the forecasted growth rate, market share, and m market size?

Who are the market's dominant players, and how have they gained a competitive advantage over their competitors?

Conclusion

The Leukemia Therapeutics Market research report's estimations and estimates examine the impact of different political, social, and economic factors, as well as current market conditions, on market growth. All of this important information will assist the reader in better understanding the market.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Protein Engineering Market Share

AI in Cancer Diagnosis Market Share

Blood Group Typing Market Share

Immunomodulators Market Share

Lymphoma Treatment Market Share

0 notes

pharmanucleus1 · 10 months

Text

Global Leukemia Therapeutics Market, Forecast 2027

Leukemia Therapeutics Market

Leukemia is a type of blood cancer caused by gene mutation leading to abnormal development of WBCs in the bone marrow and causes leukemia. Leukemia is also caused due to risk factors such as genetic disorders such as Down syndrome, previous cancer treatments, exposure to chemicals, smoking, and family history of leukemia or other blood disorders. The major types of leukemia are Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL). The majority of the AML, CML & CLL cases could be observed in adult populations, and ALL could be seen in all age groups. Leukemia treatment is based on its type, age, and ability to cope-up with the treatments.

Market Size & Growth Rate:

The leukemia therapeutics market was valued at USD 13.5 billion in 2021 and is projected to reach USD 17.1 billion by 2027, with a CAGR of 7.2% over the forecast period 2022-2027. The growth could be attributed to the return of demand to pre-pandemic levels, increasing authorization of novel & innovative medicines, extensive research, disease prevalence, and immunotherapies.

Click here for full report:

https://www.pharmanucleus.com/reports/leukemia-therapeutics-market

Market Dynamics:

On account of the growing number of people suffering from leukemia, the leukemia therapeutics treatment market has been driven by technological research & developments, the merging of healthcare organizations and new approvals in the field of blood cancer diagnostics across the globe.

The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP)-April 2021, announced five new investments in increasing the development of new and improved immunotherapies in Abintus Bio, Nexlmmune, Caribou Biosciences and Immune-Onc Therapeutics for the treatment of leukemia cancer.

Moreover, raising public awareness about the benefits of preventive healthcare is likely to move the demand for leukemia therapeutics treatment forward throughout the forecast period. Additionally, the Government initiatives and programs at increasing cancer awareness are expected to drive leukemia therapeutics treatment market expansion until 2027.

Market Drivers:

The growing research and technological development activities.

Increasing product approval and product launch by the market players are expected to propel the leukemia therapeutics market, and also technological developments are likely to create various new opportunities that will impact this leukemia therapeutics market growth in the forecast period. For instance,

In May 2022, Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) received FDA approval for combination with azacitidine in newly diagnosed AML with a susceptible IDH1 mutation in adults 75 years and older.

On June 2021, Jazz Pharmaceuticals received FDA approval for a new form of Rylaze (asparaginase erwinia chrysanthemi recombinant rywn) to be developed as part of a treatment for children and adults with ALL

In October 2021, Kite Pharma received FDA approval for use of the CAR T-cell therapy brexucabtagene autoleucel developed by Tecartus (the first CAR T-cell therapy approved) in adults with B-cell precursor ALL

In November 2018, Pfizer Inc. received U.S. FDA approval for Glasdegib (DAURISMO), the Hedgehog pathway inhibitor for the treatment of adults suffering from AML

Increasing incidence of leukemia to boost leukemia therapeutics market growth.

One of the foremost driving factors influencing the global market is the increasing prevalence of leukemia across the globe, according to the National Cancer Institute (NCI), approximately 1.5% of people were diagnosed with leukemia during their lifetime. Additionally, in the report-2022, the estimated number of living people with new leukemia cases will be 60,650, and the number of death cases will be 24,000 in the United States.

According to the American Cancer Society-2022, the CLL segment is anticipated 20,160 diagnosis cases including both children & adults in US leukemia therapeutic market, as CLL is the first line of treatment for it followed by AML and CML.

Click here for full report:

Get more details on this report - Request Free Sample

Substantial progress has been made against cancer in recent decades. As of 2019, the rate has declined by 32%, mostly because of advances in early detection and treatment for some cancers including leukemia. It reflects largely driven by progress against leukemia cancer.

Challenges:

The high cost of treatment and stringent regulatory scenario restrain the market growth.

High cost of treatment and stringent regulatory scenario restraint the market growth over the forecast period. For instance, the NCI-2022 report estimates that cancer-related direct medical costs in the US were USD 183 billion in 2015 and are projected to increase to USD 246 billion by 2030, a 34% increase based only on population growth and aging.

The low diagnosis rate of leukemia & lack of proper healthcare facilities in developing countries

Adverse reactions of leukemia therapeutics

Competitive landscape:

Novartis International AG, Bristol Myers Squibb, Sanofi S.A, Pfizer Inc., Amgen Inc., Takeda Pharmaceutical, Celgene Corporation, GlaxoSmithKline plc, Abintus Bio, Nexlmmune, Exelixis Inc., MorphoSys AG, Otsuka Holdings Company Ltd, AbbVie, Ambit Biosciences corporation, Ariad Pharmaceuticals, Gennzme Corporation, Rpche, and Others.

Key Developments:

Get more details on this report - Request Free Sample

Regional Analysis:

North America was the largest region in the leukemia therapeutics market in recent years and it is anticipated to capture the highest share of this market over the forecast period 2022-2027, with the U.S. accounting for the maximum contribution and it has well-developed structural healthcare systems. In addition, the high prevalence of leukemia and the rising geriatric population, based on the NCI-2022 report, leukemia represents 3.2% of all new cancer cases in the U.S., and the incidence rate increased in children and adolescents by about 1% per year and was stable in adults ages 20 and older. The presence significant of key players, some of the best research universities, and encouraging new product developments & launches for research lead to more significant assets in the pipeline. For instance,

In October 2022, The American Cancer Society (ACS) approved funding for 89 new Extramural Discovery Science (EDS) research grants totaling USD 54.3 million. It will fund investigators at 65 institutions across the United States from January 1, 2023.?

In November 2021, Pfizer Company acquired Trillium Therapeutics for approximately USD 2.22 billion, to enhance its oncology portfolio with the addition of next-generation immune therapies.

#Leukemia Therapeutics Market #leukemia care #global therapeutics market #innovative treatments #groundbreaking developments

0 notes

itssashasharma · 3 years

Text

Global Hemato Oncology Testing Market worth USD 4.0 billion by 2024 : Increasing Incidence of Hematologic Cancer

The study involved four major activities in estimating the current size of the hemato oncology testing market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and market sizing with industry experts across the value chain through primary research.

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for this study. According to the new market research report “Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) – Global Forecast to 2024″, published by MarketsandMarkets™, the Hemato Oncology Testing Market is projected to reach USD 4.0 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 14.8%. Browse in-depth TOC on “Hemato Oncology Testing Market“ 77 – Tables 29 – Figures 116 – Pages Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=262472877 Growth in this market is driven mainly by the rising prevalence of lymphoma & myeloma cancers, growing focus on personalized medicine, and increasing collaborations for developing assays. The services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market in 2018. Based on product & services, the market is segmented into assay kits and services. In 2018, the services segment accounted for the largest share of the product & services segment in the Hemato Oncology Testing Market. The large share of this segment can be attributed to the rising prevalence of hematologic cancers and increasing aging population. Availability of robust infrastructure and high-end equipment for conducting hemato oncology tests are the supporting factors for clinical laboratories segment Based on end-user, the Hemato Oncology Testing Market has been segmented into four types, i.e., clinical laboratories, hospitals, academic & research institutes, and other end-users. Other end-users include CROs and pharmaceutical & biotechnological companies. Clinical laboratories accounted for the largest share of the market in 2018. This segment is expected to grow at the highest rate in the coming years. This is mainly due to the presence of advanced diagnostic equipment such as analyzers and the presence of skilled professionals to perform these tests. North America accounted for the largest share of the Hemato Oncology Testing Market in 2018 North America accounted for the largest share of the Hemato Oncology Testing Market in 2018. The large share of this segment can primarily be attributed to the high incidences of hematologic cancer, aging population, awareness regarding advanced treatment methods, and the strong presence of industry players in the region. These trends are likely to drive market growth during the forecast period. Request Sample Pages:https://www.marketsandmarkets.com/requestsampleNew.asp?id=262472877 Some of the leading players in the Hemato Oncology Testing Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Germany), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), MolecularMD (Ireland), Invivoscribe, Inc. (US), Asuragen, Inc. (US), Adaptive Biotechnologies (US), ArcherDx, Inc. (US), and ARUP Laboratories Inc. (US). Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting Browse Related Reports: Molecular Diagnostics Market by Application (Infectious Disease (Hepatitis, HIV), Oncology, Genetic Testing), Technology (PCR, DNA Sequencing & NGS), End User (Hospital/Academic Laborato https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html Companion Diagnostics Market by Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), Technology (PCR, IHC, NGS, ISH), End User (Pharmaceutical & Biopharmaceutical

Companies, Reference Lab) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp

0 notes

healthcareandwellness-blog · 6 years

Link

Hypomethylating Agents Market: Introduction

Hypomethylating agents act as an essential tool in the treatment of health disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia. These are not the only available treatment options, but their use can further be integrated and optimized in a sequential treatment strategy. The hypomethylating agents are also called as DNA methyltransferase inhibitors. These have allowed the treatment of frail and higher-risk elderly patients.

Request for a sample copy of this report @ https://www.insightsandreports.com/request-sample/188

Market Dynamics

Increasing MDS cases among the population within the age group of above 50 years is one of the major reasons driving the hypomethylating agents’ market significantly. According to the American Cancer Society, the number of people who are diagnosed with MDS in the U.S. every year is unknown, but according to a study conducted by this society, around 10,000 cases are being registered in the U.S. alone, while some other estimates are much higher.

This health disorder is highly uncommon before the age of 50, and moreover, the health risks associated with disease gradually increases along with the person’s age. In the U.S., the new cases diagnosed each year are rising, as the average person’s age among the U.S. population is increasing. As the chances of disease outbreak are higher for this age group, the demand for hypomethylating agents is also predicted to grow over the forecast period.

Moreover, growing allogeneic stem cell transplants along with higher intensity approaches for the treatment of MDS, is expected to yield higher response rates and can also control the disease’s negative impact for longer times. These type of treatment facilities are increasing across the world, which will give an additional boost to the growth of hypomethylating agents market.

Hypomethylating agents market is expected to restrain, owing to the unmet need for sound treatment options among the patients. Moreover, the response rates of these agents for the control of disease’s impact is also very low, according to the National Institute of Health and American Cancer Society. These factors are expected to restrain the hypomethylating agents market significantly over the forecast period.

By Type of Treatment

By type of treatment, the hypomethylating agents market has been segmented into acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). Hypomethylating agents market for myelodysplastic syndromes is expected to have the dominant market share over the forecast period. Increasing new cases, coupled with the developing treatment options for this disorder are expected to attribute the prime share of hypomethylating agents market for myelodysplastic syndromes.

By Gender

Based on gender, the global hypomethylating agents market has been segmented into male and female. Over the forecast period, the use of hypomethylating agents for male population is projected to dominate the product use among female population. This is majorly due to the higher disease incidence chances among men, compared to women. According to the estimates by the American Cancer Society, in 2017, around 19,520 new cases of AML have been identified in the U.S. alone, out of which more than 10,670 deaths are observed, which are mostly among adults, especially among men.

By Region

North America hypomethylating agents market is expected to have the prime share in the global market over the projected period. It is majorly attributed by the increasing cases, and growing treatment facilities, along with the presence of major research organizations (NIH, ACS), and pharmaceutical companies, which are currently striving towards the research and development of new drugs to treat MDS, and AML.

Asia Pacific hypomethylating agents market is expected to witness a higher growth over the forecast period, majorly owing to the presence of key pharmaceutical companies. Manufacturing companies in this region are majorly focusing on the development of these agents, owing to the increasing cases of MDS and AML. Moreover, the governing bodies of several countries in this region are majorly focusing on the development of healthcare industry, which will provide lucrative opportunities for the hypomethylating agents market to grow over the forecast period.

Competitive Landscape

Some of the prominent players in the global hypomethylating agents market include Pfizer, Blue Point Laboratories, Actavis Pharma Company, Dr. Reddy’s Laboratories, Celgene, Cipla Limited, Otsuka Pharmaceuticals, Astex Pharmaceuticals, etc. among others.

Some key pharmaceutical companies such as Cipla Limited and Otsuka Pharmaceuticals are working constantly to get FDA approvals of the drugs developed. For instance, Cipla Limited received a final approval from the U.S. FDA for its generic drug Dacogen in November 2017.

Also, many prominent players are trying to obtain the rights from generic drug manufacturers to expand their geographic horizon in the global hypomethylating agents market. For instance, in March 2014, Otsuka Pharmaceuticals acquired rights from EISAI Inc. for the development and marketing of Dacogen in U.S., Canada, and Japan markets.

For more information about this report @ https://www.insightsandreports.com/industry-reports/hypomethylating-agents-market

About Us:

Insights and Reports is a research and consulting group assisting the clients with 360-degree insights with real time qualitative and quantitative information. The Insights and Reports team is valued for continuous client-oriented services. Our data scientists monitor the markets pertaining to their expertise on a daily basis with the help of 150+ analysts to back them with accurate market studies.

Mr. Saby

Insights And Reports

2201 Cooperative Way #600,

Herndon, VA 20171, USA.

Tel: +1 703 574 4447

Email: [email protected]

#Hypomethylating Agents Market Report #Hypomethylating Agents Market #Global Hypomethylating Agents Market #Hypomethylating Agents Market Analysis #Hypomethylating Agents Market Growth #Hypomethylating Agents Market Demand #Hypomethylating Agents Market Trends #Hypomethylating Agents Market Demand Growth

1 note · View note

kennethresearch · 3 years

Text

Global Asparaginase Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Global Asparaginase Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Asparaginase Market products.

Get Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

It is also anticipated to grow on account of the growing demand for chemicals from the end users, backed by the increasing consumption of chemicals across different industries and the rising need for advanced chemicals. In India, the production of major chemicals and petrochemicals during the period 2020-2021 was close to 12000 thousand MT. Additionally, between the period 2015-16 and 2019-20, the production of the chemicals and petrochemicals in the nation grew at a CAGR of close to 6%.

Global Asparaginase Market is valued approximately at USD XXX million in 2018 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2019-2026. Asparaginase is an enzyme which catalzes the hydrolysis of l-asparagine to l-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. These are used widely in Healthcare industry and Food manufacturing industry as a medication. It is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. As Asparaginase was approved for medical use in the United States in 1978. It is also on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Asparaginase is used in the food manufacturing to reduce the formation of acrylamide. Acrylamide is a carcinogen in the starch containing food products such as biscuits and snacks. Thus, the rapidly growing healthcare and food manufacturing industry increase the demand for Asparaginase during the forecast period. As the Food and drinks market in Europe contributed to be the largest manufacturing sector in 2017 with a turnover of USD 1222 billion. The same sector invested USD 3.12 billion in research & development in 2017 which shows a positive sign in the market growth. Further, the rising investments of the market players for the research and development and production of Asparaginase according to the regulatory specification due to the rise in demand further fuels the market growth. However, the side effects of Asparaginase on human body such as mild bone marrow suppression, pancreatitis, anticoagulant factor resulting in stroke and bleeding hinders the market growth.

The regional analysis of global Asparaginase market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the dominant pharmaceutical industry in the region which is the major industry which uses Asparaginase enzyme. Further rising cases of Leukemia in the region propel the market growth. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing population along with increasing disposable income coupled with growing food manufacturing industry would create lucrative growth prospects for the Asparaginase market across Asia-Pacific region.

Major market player included in this report are: Jazz Pharmaceuticals Plc Shire Plc Medac GmbH Kyowa Hakko Kirin Co., Ltd. Qianhong Bio-pharma Taj Pharmaceuticals Mingxing Pharma Exova SL Pharma Inc United Biotech Pvt. Ltd. Novus Biologicals The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Escherichia Coli Erwinia Chrysanthemi Pegylated By Application: Healthcare Food Industry Others By Region: North America U.S. Canada Europe UK Germany Asia Pacific China India Japan Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017 Base year – 2018 Forecast period – 2019 to 2026

Target Audience of the Global Asparaginase Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investor

Download Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys & Opportunity Outlook

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Kenneth Research

Email : [email protected]

Phone: +1 313 462 0609

0 notes

marketresearchtrendsblog · 3 years

Text

Leukemia Therapeutics Market By Therapy Analysis, Trends – Global Forecast by 2020 - 2025

Uncontrolled growth of cells is caused due to mutation to genes in cancer. The uncontrolled grown cell again moves from one part of body to another through blood and lymph system. There are different types of cancer out of which Leukemia is one. Cancer which is formed in blood tissues is called as Leukemia. Leukemia occurs due to the uncontrolled growth of with blood cells in the bone marrow. White blood cells are the protectors of our body from different infections. Leukemia is the most common type of cancer that is caused among adult males because they are not diagnosed at proper time. The most familiar syndrome of Leukemia is weight loss, night sweats, fever, frequent infections and enlarged liver size. There are different types of Leukemia out of which are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia.

How Big is the Global Leukemia Therapeutics Market?

The Global Leukemia Therapeutic Market is expected to be around US$ 13 Billion by 2025 at a CAGR of 4% in the given forecast period.

The major driving factors of Global Leukemia Therapeutic Market are as follows:

Novel developments for drug discovery approaches Increase incidence number of target disease Increase aging population Not much competition in the market

The restraining factors of Global Leukemia Therapeutic Market are as follows:

Expensive treatment Adverse effect of the treatment

Read more information about Global Market with Impact of Covid-19

To get Sample Copy of Business Report through this link: https://www.sdki.jp/sample-request-105927

The Global Leukemia Therapeutic Market is segmented on the lines of its therapy, type and regional. Based on therapy segmentation it covers Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy, other. Based on type segmentation it covers Chronic leukemia, acute leukemia, others. The Global Leukemia Therapeutic Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

This report provides:

An overview of the global market for Global Leukemia Therapeutic Market and related technologies.

Analyses of global market trends, with data from 2016, estimates for 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2025.

Identifications of new market opportunities and targeted promotional plans for Global Leukemia Therapeutic Market.

Discussion of research and development, and the demand for new products and new applications.

Comprehensive company profiles of major players in the industry.

REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets on Global Leukemia Therapeutic Market with the reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc. Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.

The Global Leukemia Therapeutic Market has been segmented as below:

By Therapy Analysis:

Chemotherapy Biological Therapy Radiation therapy Targeted therapy Other

By Type Analysis:

Chronic leukemia Chronic lymphatic leukemia Chronic myeloid leukemia Acute leukemia Acute lymphatic leukemia Acute myeloid leukemia Others

By Regional Analysis:

North America Europe Asia-Pacific Rest of the World

Reasons to Buy this Report:

Obtain the most up to date information available on all Global Leukemia Therapeutic Market.

Identify growth segments and opportunities in the industry.

Facilitate decision making on the basis of strong historic and forecast of Global Leukemia Therapeutic Market data.

Assess your competitor’s refining portfolio and its evolution.

Original Source of this content: https://www.sdki.jp/reports/leukemia-therapeutics-market/105927

For more information, Please contact us now:

Shibuya Data Count

Email: [email protected]

Tel: + 81 3 45720790

0 notes

kenresearch1 · 11 months

Text

Top 3 US Pharmaceutical Companies and Their Strategies in US Acute Myeloid Leukemia Market

Buy Now

US Acute Myeloid Leukemia Market is growing due to advancement in treatment approaches, increase healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Story Outline

Pfizer Inc.- An American multinational company with the highest annual revenue of around 100 billion US$ in 2022 in the drug market. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investment in research and development.

Brystol Myers Squibb- One of the largest American pharmaceutical companies which consistently ranks on the Fortune 500 list of the largest US corporations. The company’s mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases.

Novartis AG- The company with the fourth-largest revenue in the drug market which is focused to deliver high-value medicine that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

The US Acute Myeloid Leukemia Market is expected to grow at CAGR of 10.5% in the forecast period 2022-2028.

The Acute Myeloid Leukemia Market of US is driving growth at an amazing level. This surge is a result of advancement in treatment approaches, increases healthcare costs and expenditure, growing investments in Research and Development, and a constant growth in population.

Various pharmaceutical companies are actively shaping this growing market with their strategies and innovations.

This article provides an in-depth look at major pharmaceutical companies with their strategies and innovations.

1.Pfizer Inc.

Click here: To know more about Pfizer Inc.

Pfizer Inc. is an American multinational pharmaceutical company and headquartered at The Spiral in Manhattan, New York City. The company has made significant contributions to the US Acute Myeloid Leukemia Market through a sophisticated, robust, agile manufacturing infrastructure and investing in research and development.

The company employs more than 30,000 employees worldwide, have 35+ manufacturing sites, 300+ external suppliers, and have reached more than 180 countries. Pfizer tops the list of drug market by achieving a revenue of approx. 100 billion USD in 2022.

Pfizer has made significant contributions to the US acute Myeloid Leukemia Market. Some notable contributions are, in April 2017, the development and approval of a targeted therapy called “Rydapt”, which is an oral kinase inhibitor that targets multiple enzymes, including FLt3, which is often mutated in AML patients. The drug was approved by FDA in April 2017 for use in combination with Chemotherapy.

Furthermore, MYLOTARG is approved in combination with daunorubicin and cytarabine for the treatment of patients aged 15 and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except Acute Promyelocytic Leukemia (APL).

The company’s purpose is “Breakthroughs that change patients' lives—fuels everything we do and reflects our passion for building on our legacy as one of the greatest contributors of good to the world.

The company says that its purpose ensures that its patients remain at the center of all that they do. They live with their purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to their medicines.

Pfizer believes in growing partnerships with innovators to initiate forward great science and continually seek new partners that are actively researching bold scientific ideas. In December 2022, Pfizer announced its collaboration with Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic using large-scale human-based data.

Pfizer’s continuous clinical trials and collaboration with healthcare institutions and research organizations has majorly contributed in advancing Acute Myeloid Leukemia Market and the development of novel treatment strategies.

2.Bristol Myers Squibb

Click here: To Download a Sample Report

The Bristol Myers Squibb Company, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. BMS is one of the world’s largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest US corporations.

The company employs more than 34,000 across more than 86 locations worldwide. The company’s revenue in 2022 was approximately 46 bn USD.

Their mission is to discover, develop, and deliver innovative medicines that help patients as well as prevail over serious diseases. Bristol believes in the power of science to address some most challenging diseases of today's world.

Bristol Myers is majorly known for its contributions to oncology, and immunology and its involvement in Acute Myeloid Leukemia Market with its broader focus on cancer treatments.

The significant development of BMS can be noted from June 2021, Bristol Myers Squibb received approval from European Commission for Onureg, a Frontline oral maintenance therapy for adult patients with acute Myeloid Leukemia who achieved their first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy. Onureg is expected to increase sales and product revenue, thereby increasing the US Acute Myeloid Leukemia Market growth.

Furthermore, the strategic cooperation between Evotec and Bristol Myers Squibb has grown in order to create a pipeline for programs addressing more neurological illnesses. In order to find altering therapies for a variety of neurodegenerative disorders, the firms started working together in 2016. The eight-year extension is intended to strengthen the strategic partnership even more.

3.Novartis AG

Click Here : To Download a Custom Report

Novartis AG is a healthcare company that majorly focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical and eye care products. Novartis offers generic medicines and biosimilars through Sandoz. The company conducts its research through The Novartis Institute for Biomedical Research (NIBR).

Novartis is one of the largest pharmaceutical companies in the world and the fourth largest by revenue in 2022, which was approx. 50.500 billion USD.

The company is functioning in more than 150 locations with around 1,10,000 employees working worldwide.

Novartis's strategy as a focused medicines company is to deliver high-value medicine that alleviates society’s greatest disease burdens through technology leadership in R&D an novel access approaches.

Novartis contribution to Acute Myeloid Leukemia Market includes, FDA approval of Novartis Scemblix (asciminib), with novel mechanism of action for the treatment of Leukemia in October,2021.

Furthermore, through their open approach Novartis is focusing on new technologies to develop next generation therapeutics. Currently, Novartis is working with Orionis Bioscience to find new targets at a genome-wide scale.

By combining development and drug discovery with innovation, they aim to achieve tenuous targets and to launch novel small molecule therapy for Acute Myeloid Leukemia patients more quickly. Thus driving a steered growth for the US Acute Myeloid Leukemia Market.

0 notes

healtcare · 3 years

Text

Global Haematology and Flow Cytometry Market

Global Haematology and Flow Cytometry Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Hematology is a medical specialty that deals with the study and treatment of blood. This is concerned with the diagnosis, study, treatment, and prevention of blood diseases. Flow cytometry is an analytical tool that is used in the measurement and analysis of several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to subclassify cell types to decide on the best treatment plan.

Global Haematology and Flow Cytometry Market Dynamics:

Rising global incidence and prevalence of chronic diseases like blood cancer is the major driving factor for the market growth. According to the National Cancer Institute in 2018, it was being estimated that 60,300 new leukemia cases are diagnosed and the deaths are around 24,470 cases in the United States. The increasing number of HIV cases globally is an important driver for the flow cytometry market. This is because the flow cytometry technique has its direct application in HIV diagnosis. According To UNAIDS in 2017, 31.1-43.9 million people globally are living with HIV by out of which 1.8 million are newly affected with HIV. Flow cytometry uses light scattering to determine the identity of cells. Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives. ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth. The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

The Global Haematology and Flow Cytometry Market is segment on the basis of Product, Technology and End-Users. Based on Product, the flow cytometry instruments segment is expected to dominate the global market. The segment is further classified into cell analyzers and cell sorters. It held a market share of 25% in 2020. This high share is attributed to new advancements in technology and the introduction of novel cytometers by key players. The high price of these instruments is also contributing toward the high revenue generation in this segment. Along with this, reagents and consumables also held a prominent share in 2020. Owing to their increased adoption in diagnostics and research the segment is expected to register lucrative growth over the forecast period. The large share of this segment is mainly attributed to the growing research activities to develop and prove the efficacy of various assays and kits, and the commercialization of high-quality and application-specific consumables, reagents, and assays. Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years. To know about the Research Methodology :- Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

North America dominated the global market in 2020. The region dominated the global market in 2020 by holding a market share of 39.1%. This dominance is attributed due to the United States' high healthcare spending, well-developed healthcare system, and widespread adoption of technologically advanced flow cytometry solutions. In addition, the established pharmaceutical industry, as well as extensive research activities by research universities and pharmaceutical companies has generated huge demand for flow cytometry solutions for research universities and pharmaceutical companies have created a huge demand for flow cytometry solutions for research needs. APAC region is projected to exhibit highest CAGR during forecast period. This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

• In September 2018, the U.S. FDA awarded a grant of ~$18 million over a period of four years for 12 new clinical trials. These clinical trials are aimed at developing products for patients with rare diseases (including primary sclerosing cholangitis, stargardt disease, Cushing disease, acute myeloid leukemia, and graft versus host disease, among others). • In March 2017, Cytek Biosciences Inc., a manufacturer and supplier of flow cytometry products and services launched its DxP Athena flow cytometry system. The system is compact, powerful, easy-to-use cell analyzer that are typically only found in conventional instruments that come with a much higher price tag. The DxP Athena makes the benefits of flow cytometry which are more readily available to larger number of researchers by its compact size. • In 2016, the Global Clinical Trials Fund (U.K.) launched a dedicated fund with an upper limit of $662,185 to support clinical trials across the world related to the testing of new experimental drugs and existing drugs developed for dementia.

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

• Becton, Dickinson and Company • Beckman Coulter, Inc. • Bio-Rad Laboratories, Inc. • Thermo Fisher Scientific, Inc. • Merck KGaA • Sysmex Partec GmbH • Luminex Corporation • Miltenyi Biotec GmbH • Sony Biotechnology • Abbott • Agilent Technologies • CellaVision • Horiba • Nihon Kohden • Ortho-Clinical Diagnostics • Roche • Siemens Healthineers • Sysmex • Miltenyi Biotec • Apogee Flow Systems Ltd.

#Haematology #Flow Cytometry #Haematology and Flow Cytometry

0 notes

itssashasharma · 3 years

Text

Global Hemato Oncology Testing Market worth $ 4.0 billion by 2024 : Increasing Incidence of Hematologic Cancer

Lab) – Global Forecast to 2022 https://www.marketsandmarkets.com/Market-Reports/companion-diagnostics-market-155571681.html About MarketsandMarkets™ MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Shelly Singh MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/hemato-oncology-testing-market.asp Visit Our Website: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/hemato-oncology-testing.asp

0 notes

rdagade · 3 years

Text

Global Haematology and Flow Cytometry Market

is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 8.5% during forecast period.

Global Haematology and Flow Cytometry Market Overview:

Global Haematology and Flow Cytometry Market Dynamics:

Increasing adoption of flow cytometry techniques in research and academia and growing initiatives in the field of immunology and Immuno-oncology researches are expected to propel the growth of the global flow cytometry market. Growth in stem cell research and the development of high-throughput flow cytometry technologies are likely to add new opportunities for this market in the coming years. Increasing regulatory approval and the introduction of technologically advanced flow cytometry solutions are expected to facilitate market growth over the forecast period. For instance, in June 2020, Sysmex Corporation launched the XF-1600 flow cytometer for laboratories, in North America. A significant restraint on the flow cytometry market is the availability of cheaper and better alternatives.

ELISA (enzyme-linked immunosorbent assay) and radioimmunoassay are two of these alternatives. Although flow cytometry, ELISA, and radioimmunoassay are all methods for detecting "problem cells" in a community of cells, ELISA and radioimmunoassay are less expensive and easier to use. Along with this, the dearth of skilled technicians for managing such advanced technology is expected to restrain the market growth.

The report has profiled twenty key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Haematology and Flow Cytometry Market Segment Analysis:

Based on technology, the cell-based flow cytometry segment held the largest market share of 76% in 2020. The highest share is due to an increase in demand for early diagnosis and increased understanding of the related benefits of cell-based assays. In addition, advances in cell-based assay technology, such as innovations in tools, labels, affinity reagents, software, and algorithms, are expected to accelerate adoption in the coming years.

To know about the Research Methodology :-

Request Free Sample Report

Global Haematology and Flow Cytometry Market Regional Insights:

This high growth can be attributed to the extensive growth in the pharmaceutical and biotechnology industries of emerging economies, such as China and India. The lucrative growth exhibited by this region is also an outcome of continuous government support for the establishment of the pharmaceutical industry in emerging countries. The report also helps in understanding Global Haematology and Flow Cytometrys Market dynamics, structure by analyzing the market segments and project the Global Haematology and Flow Cytometrys Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Haematology and Flow Cytometrys Market make the report investor’s guide.

Global Haematology and Flow Cytometry Market, key developments:

For more information visit@ https://www.maximizemarketresearch.com/market-report/global-haematology-and-flow-cytometry-market/98749/

Global Haematology and Flow Cytometry Market Scope: Inquire before buying

Global Haematology and Flow Cytometry Market, by Region:

• North America • Europe • South America • MEA • APAC

Global Haematology and Flow Cytometry Market, Key players:

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [email protected]

Address: Omkar Heights, Sinhagad Road, Manik Baug, Vadgaon Bk,Pune, Maharashtra 411051, India.

Contact: +919607195908

#Global Haematology and Flow Cytometry Market

0 notes

techscimarketresearch · 3 years

Text

Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research

Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.

According to TechSci Research report, “Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, the global cancer biopsy market is projected to show a robust growth in the forecast period from 2022 to 2026. The market growth can be attributed to the surge in the demand of early and efficient diagnostic of the various types of cancerous diseases that are prevailing, thus it is influencing the global cancer biopsy market, as biopsy is one of the diagnostic procedures for the cancerous cells. Moreover, technologically advanced medical devices are being developed that have been quite handful in the categorization of the cancer. Along with the diagnosis of the malignancy, these devices are also actively responsible in identifying the histology of the cancer as well as staging of the cancer thereby understanding the level of risk the patient is at. These advents are actively driving the growth of the global cancer biopsy market in the next five years until 2026.

Cancer is a chronic disorder that can be defined as the mass of unregulated cell growth that take place in a form of lump. They do not perform the set of functions they are expected to perform and rather multiply immaturely causing bumps and mass of cells that clutter at a single place. These clusters of cancerous cells may grow due to various reasons like, genetic abnormalities, environmental factors, virulent vectors or due to excessive exposure to various harmful radiations. Some chemical factors like poisonous chemical exposure may trigger the cancer causing genes and there by cause cancer. Cancer biopsy is a method of scoping and dissecting a piece of cancerous mass from the cancer affected area of the body and retrieving it for the further processes like diagnosis or research, etc. The recent trend has seen a shift in the method of biopsy, instead of tumor biopsy, experts are choosing liquid biopsy. Liquid biopsy is the sampling and analysis of non-solid biological tissue, preferably blood. This method is non-invasive and has provision of early diagnosis through screening and determines the risk of relapse of cancer after treatment. With the presence of biomarkers it can be beneficial in determining the best treatment plan as well as aids the research towards mechanism of resistance, disease progression, and identification of newer treatments.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

The global cancer biopsy market is segmented on the basis of product, type of biopsy, application, end user, competitive landscape, and regional distribution. Based on type of biopsy the market is further bifurcated into tissue biopsies, liquid biopsies, and others. Liquid biopsies are anticipated to hold the largest market share owing to the increased demand for non-invasive method of diagnosis and research sampling procedures. Liquid biopsies require kits and consumable that are products required for the cancer biopsies which is co-dependently driving the market growth in the forecast period, until 2026. Tissue biopsies are sub-categorized into needle and surgical biopsies. Tissue biopsies are also expected to hold significant share of the market owing to the need of surgical graft of the tissues that are solid or if the cancer cells are not available in the blood. In certain cases, like breast cancer experts have to perform a surgical biopsy to reach the endothermal cells, or sometime needle biopsy is used in throat cancer. Increasing instances of these cancers is driving the growth of the market towards and is expected to continue in the forecast period as well.

Needle biopsies are the most popular choice among the experts owing to the efficiency, shorter wait time for the results (with fine needle aspiration, FNA type needle biopsies). Although various techniques demand surgical incisions like staging splenectomy for Hodgkin’s lymphoma patients. To perform these procedures with 100% efficiency the experts require right biopsy type for the right patients, appropriate sample processing, and accurate pathological examination, which is driving the market growth in the next five years.

Some of the major competitors in the market are Qiagen N.V., Illumina, Inc., ANGLE Plc, Becton, Dickinson and Company, Myriad Genetics Inc., Hologic, Inc., Biocept, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Lucence Diagnostics Pte. Ltd., GRAIL, Inc., Guardant Health Inc., Exact Sciences Corporation, Freenome Holdings, Inc., among others. Other strategies include forming partnerships among the market players and the research institutions, and technological advanced products and services launches in the forecast period.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399

Customers can also request for 10% free customization on this report.

“Image guided biopsies, and related technological advancements are in trend in the market. Through a recent study, multi-parametric MRI was confirmed to minimize the false-negative results thereby enhancing the risk assessment. North American region is anticipated to hold the largest market share owing to the excellent healthcare industry that is well established along with the United States Food and Drug Administration approved procedures that increased value for the Clinical Laboratory Improvement Amendment (CLIA)‐developed tests,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Cancer Biopsy Market By Product (Instruments, Kits and Consumables, Services), By Type of Biopsy (Tissue Biopsies (Needle and Surgical Biopsies), Liquid Biopsies, Others), By Application (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Others), By End User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers), By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cancer biopsy market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cancer biopsy.

Browse Related Reports:

Asia-Pacific Cancer Diagnostics Market By Diagnostic Type (Lab Testing, Genetic Testing, Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy and Others), By Technology (Platform Based, Instrument Based, Tumor Biomarker Tests), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Skin cancer, Others), By End-User (Diagnostic Centers, Hospitals and Clinics, Research Institutes and Others), By Company, By Region, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html

Global Leukemia Therapeutics Market By Type (Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Others), By Gender (Male, Female), By Age Groups (0-15, 15-30, 30-50, 50+), By Diagnosis (Blood Test, Biopsy, Physical Exam, Imaging), By Treatment (Chemotherapy, Stem Cell Transplantation, Immunotherapy, Targeted Therapy, Others), By Drugs (Tyrosine Kinase Inhibitors, Antimetabolites, Hormones (Corticosteroids), Monoclonal Antibodies, Others), By Route of Administration (Oral, Parenteral), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Healthcare #Cancer Biopsy Market #Global Cancer Biopsy Market #Cancer Biopsy Market Size #Cancer Biopsy Market Share #Cancer Biopsy Market Trend #Cancer Biopsy Market Forecast #Medical Devices

0 notes

techsciresearch · 3 years

Text

Cancer Biopsy Market to Grow at an Impressive CAGR During the Forecast Period | TechSci Research

Research and development growth to drive the growth of Global Cancer Biopsy Market, in the forecast period, 2022-2026.

Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on "Global Cancer Biopsy Market"

https://www.techsciresearch.com/report/cancer-biopsy-market/7399.html

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7399

Customers can also request for 10% free customization on this report.

Browse Related Reports:

https://www.techsciresearch.com/report/asia-pacific-cancer-diagnostics-market/7303.html

https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

#TechSci #Market Research Reports #Global Cancer Biopsy Market #Cancer Biopsy Market #Cancer Biopsy Market Size #Cancer Biopsy Market Share #Cancer Biopsy Market Trend #Cancer Biopsy Market Forecast #Healthcare

0 notes

cool-akashy-maximize · 3 years

Text

Global Leukemia Therapeutics Market : Industry Analysis and Forecast (2019-2027)

Global Leukemia Therapeutics Market was valued at US$ 11.32 Bn in 2019 and is expected to reach US$ 19.2 Bn by 2027, at a CAGR of 7.84 % during the forecast period.

The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region. Global Leukemia Therapeutics MarketGlobal Leukemia Therapeutics Market Dynamics:

Increased prevalence of cancer especially blood cancer across the globe is leading to increasing demand for effective treatments, which is the driving factor for market growth. Increase in expenditure on the development of novel treatment and developing health infrastructure is further driving the market growth. Additionally, the growth in survival rate and minimum side effects of novel treatment such as stem cell therapy, bone marrow transplant has open new avenues for market growth. Also, increased exposer to chemical mutation, changing dietary habits, and the living style of the population is further pushing the market growth.

The lack of early diagnosis and awareness among the public are leading challenges in the market for leukemia therapeutics. Furthermore, redefining the drug lifecycle roadmap is a major challenge for drug innovators. However, breakthrough therapy designations and accelerated approvals granted by regulatory bodies like the FDA would offer lucrative market opportunities for the drug innovators. Segment Analysis of the Global Leukemia Therapeutics Market:

Based on treatment type, chemotherapy led the segment in 2019. Because of its ability to kill cancerous cells or inhibiting their proliferation and maintain a normal level of lymphocytes of chemotherapy, is driving the market growth. Similarly, the increased survival rate of the patients treated with chemotherapy is again fueling its demand.

On the basis of the type of leukemia, acute lymphocytic leukemia is dominating the segment and has accounted for maximum market share. Owing to the rising condition of cancerous cells, acute leukemia is driving the segment growth. Increasing smoking habits, exposure to chemicals, radiation, and cases with other blood-related disorders are again driving the segment growth. Regional Insights of the Global Leukemia Therapeutics Market:

In terms of region, North America followed by Europe dominates the global leukemia therapeutics market owing to the growing incidence of cancer and increasing aging population. The APAC is expected to show a high growth rate because of the increasing incidence of cancer. China and India are expected to be the fastest-growing leukemia markets in the Asia Pacific region. Some of the key driving forces for the leukemia therapeutic market in emerging economies are increasing R&D investment, a large pool of patients, and growing government funding.

Key developments in leukemia therapeutics market: In February 2018, Sanofi announced to discard the mid-stage exertion on ALL therapy for the anti-CD38 antibody isatuximab. Also, Erytech Pharma broadened the scope of eryaspase (GRASPA) growth for solid tumors further clinical studies in triple-negative breast cancer.

The objective of the report is to present a comprehensive assessment of the market and contain thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Leukemia Therapeutics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. Scope of the Global Leukemia Therapeutics Market Report:

Global Leukemia Therapeutics Market, by Type of Leukemia

• Chronic Myeloid Leukemia • Chronic Lymphocytic Leukemia • Acute Lymphocytic Leukemia • Acute Myeloid Leukemia

Global Leukemia Therapeutics Market, by Treatment Type

• Targeted Drugs & Immunotherapy • Chemotherapy

Global Leukemia Therapeutics Market, by Molecule Type

• Small Molecules • Biologics

Global Leukemia Therapeutics Market, by Mode of Administration

• Oral Mode • Injectable Mode

Global Leukemia Therapeutics Market, by Gender

• Males • Females

Global Leukemia Therapeutics Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America Key Players Operating in the Global Leukemia Therapeutics Market:

• Novartis AG • AbbVie • Bristol-Myers Squibb • Hoffmann-La Roche • Sanofi • Pfizer • Amgen • Gilead Sciences • Takeda • Celgene • AbARIAD Pharmaceuticals, Inc. • F. Hoffmann-La Roche Ltd. • Genzyme Corporation • GlaxoSmithKline plc. • Teva Pharmaceuticals • Allergan, • AstraZeneca, • F. Hoffmann-La Roche Ltd, • Pfizer Inc., • Merck KGaA, Merck & Co., Inc.,

For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

0 notes

fostermarketarch · 3 years

Text

Nanopharmaceuticals Market Comprehensive Analysis And Vendor Landscape 2027

The global Nanopharmaceuticals market was valued at US$ xx million in the year 2019. The market is estimated to be valued at US$ xx million in the year 2020, and is expected to reach US$ xx million by the year 2027, with an estimated CAGR of xx% during the forecast period (2021-2027). The research study also includes exhaustive information about market dynamics such as drivers, restraints, opportunities, technological advancements, future trends, supply chain analysis, patent landscape, pricing analysis, regulatory and reimbursement framework for precise market estimations and forecasts.

Additionally, the business intelligence study encompasses the COVID-19 scenario as follows:

· Long-Term, Mid-Term, and Short-Term Impact of COVID-19

· Pre- and Post-COVID-19 Scenario

· Disruptions in the Supply Chain

Get Free PDF Brochure Of This Report @ https://www.fostermarketresearch.com/product/industry/10/160/Pdf%20Brochure/

Competitive Insights

Leading and emerging companies of the global Nanopharmaceuticalsmarket were identified based on their current offerings. Further, the Nanopharmaceuticals industry is one of the most competitive industries, with the leading players actively competing against each other to gain a greater share in the industry. Some of the major companies in the Nanopharmaceuticals market are: BlueWillow Biologics, EnColl Corporation, EyePoint Pharmaceuticals, Lena Nanoceutics Ltd., NanoSpectra biosciences Inc., Nanobiotix, Starpharma Holdings Ltd., Selecta Biosciences, Cristal Therapeutics, Celgene Inc., Aquanova AG, Nanology LLC, and Others

The competitive landscape of the Nanopharmaceuticals industry exhibits an inclination towards emerging strategies including product launches, partnerships, collaborations and contracts, acquisitions, funding, and other developments to achieve the objectives faster.

Our reports fill up the gaps and provide you with all the detailed analysis of competitive companies involving:

· Analyzing competitive strategies and techniques

· Competitive positioning of key players

· PORTER’s and SWOT analysis for competitive risk analysis

· Competitive Share Analysis

· Financial analysis of players to determine their withstand capacity

· Analyzing their sales path and product study

For More Information Of This Report @ https://www.fostermarketresearch.com/product/industry/10/160/

Key Segments Covered in the global Nanopharmaceuticals market report are:

· By Carrier Type: (Liposomes, Polymer, Nanocrystals, Protein, Inorganic, and Others)

· By Application: (Oncological diseases, Neurological Diseases, Orthopedic Disorders, Cardiovascular Diseases, Infectious Diseases, Urological Diseases, Others)

Regional Coverage:

The global Nanopharmaceuticals market segregates into five regions including North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. North America followed by Europe held the major share of the global market (in terms of value) in 2020. However, Asia-Pacific region exhibit highest CAGR (%) during the forecast period (2021-2027). Our research study further sub-divides regions into countries as follows:

· North America - the U.S. and Canada

· Europe - Germany, the U.K., France, Spain, Italy, Russia, and Rest-of-Europe

· Asia-Pacific - China, India, Japan, South Korea, Australia, ASEAN, and Rest-of-Asia-Pacific

· Latin America - Mexico, Brazil, and Rest-of-Latin America

· Middle East and Africa - Gulf Cooperation Council (GCC) Countries, South Africa, Israel, and Rest-of-Middle East and Africa

Market Dynamics:

Technological advancements in the healthcare industry have always played a crucial role in development of Nanopharmaceuticals market. The major factors driving the growth of this market are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in the global healthcare expenditure, and rapid growth in the aging population. In August 2017, the company, Jazz Pharmaceuticals received FDA approval for Vyxeos. Vyxeos is basically used for the treatment of acute myeloid leukemia. However, factors such as less solubility of nano-pharmaceuticals and toxicity issues, may hinder the growth of the nanopharmaceutical market.

Buy Now This Business Strategic Report To Improve Your Profits @ https://www.fostermarketresearch.com/product/buy/10/160/

About Foster Market Research:

Foster Market Research is a global market intelligence and advisory firm engaged in providing data-driven research extract from rigorous analysis, to the clients to make critical business decisions and execute them successfully. Foster connects over various distribution channels and numerous markets for great understanding of the trends and market to deliver our clients with accurate data.

Our focus is on providing market research that delivers a positive impact on your business. We work continuously to provide our clients with the most accurate analytics data and research reports without any delay so as to improve their business strategies and provide them with rich customer experience.

1701 Royal Lane,

#1306, Dallas

Tx-75229

Phone: +1 469 4981929

Email: [email protected]

0 notes